Swedish Orphan Biovitrum AB (publ) (SOBI.ST)
| Previous close | 231.60 |
| Open | 231.40 |
| Bid | 231.20 x 0 |
| Ask | 231.30 x 0 |
| Day's range | 230.50 - 232.30 |
| 52-week range | 177.45 - 245.50 |
| Volume | |
| Avg. volume | 372,454 |
| Market cap | 68.463B |
| Beta (5Y monthly) | 0.37 |
| PE ratio (TTM) | 22.52 |
| EPS (TTM) | 10.27 |
| Earnings date | 08 Feb 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 255.44 |
- PR Newswire
Invitation: Sobi's Q4 and FY 2022 report
Sobi plans to publish its report for the fourth quarter and full year of 2022 on 8 February 2023 at 08:00 CET.
- PR Newswire
NEJM publishes data demonstrating clinically meaningful prevention of bleeds and superior bleed protection for efanesoctocog alfa
Pivotal study data published in The New England Journal of Medicine (NEJM) continues to highlight the efficacy, safety, and pharmacokinetic profile of efanesoctocog alfa (formerly BIVV001), a potential new medicine for haemophilia A. These data demonstrate the clinical benefits of normal to near-normal factor activity levels (>40%) for the majority of the week achieved by once weekly efanesoctocog alfa dosing. Efanesoctocog alfa is currently under priority regulatory review in the US with a targ
- PR Newswire
Zynlonta® (loncastuximab tesirine) approved in the EU for the treatment of relapsed or refractory diffuse large B-cell lymphoma
Sobi® and ADC Therapeutics SA today announced that the European Commission (EC) has granted conditional marketing authorisation for the use of Zynlonta® (loncastuximab tesirine) for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The approval follows a positive opinion issued in September by the Committee for Medicinal Products for Human Use of the European Medicines Agency (EMA).
